Durvalumab vs Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D

## Durvalumab vs Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D — N/A.

## Chemical Properties

**Type**: Durvalumab — Antibody; Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D — Vaccine component.